Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria

Chloroquine or dihydroartemisinin-piperaquine with either 7- or 14-day primaquine regimens provided highly effective radical cure of vivax malaria on the Thailand-Myanmar border. Short course higher dose primaquine regimens for vivax malaria radical cure may improve efficacy by improving adherence.

[1]  H. Win,et al.  Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Georgina S. Humphreys,et al.  The Vivax Surveyor: Online mapping database for Plasmodium vivax clinical trials , 2017, International journal for parasitology. Drugs and drug resistance.

[3]  H. Win,et al.  Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens , 2017, PLoS medicine.

[4]  I. Elyazar,et al.  Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia , 2015, BMC Medicine.

[5]  S. Krudsood,et al.  Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study , 2014, The Lancet.

[6]  J. Crump,et al.  Evaluation of In-Hospital Management for Febrile Illness in Northern Tanzania before and after 2010 World Health Organization Guidelines for the Treatment of Malaria , 2014, PloS one.

[7]  F. Nosten,et al.  Malaria Burden and Artemisinin Resistance in the Mobile and Migrant Population on the Thai–Myanmar Border, 1999–2011: An Observational Study , 2013, PLoS medicine.

[8]  Q. Bassat,et al.  Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. , 2012, The Journal of infectious diseases.

[9]  R. Price,et al.  Dihydroartemisinin-Piperaquine Versus Chloroquine in the Treatment of Plasmodium vivax Malaria in Thailand: A Randomized Controlled Trial , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  J. Baker,et al.  Evaluation of the safety and tolerability of a short higher-dose primaquine regimen for presumptive anti-relapse therapy in healthy subjects. , 2011, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[11]  J. Schumi,et al.  TRIALS REVIEW Open Access , 2022 .

[12]  J. Kaewkungwal,et al.  Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border , 2010, Malaria Journal.

[13]  Joan Muela Ribera,et al.  Adherence to 7-Day Primaquine Treatment for the Radical Cure of P. vivax in the Peruvian Amazon , 2010, The American journal of tropical medicine and hygiene.

[14]  N. Day,et al.  A Comparison of Two Short-Course Primaquine Regimens for the Treatment and Radical Cure of Plasmodium vivax Malaria in Thailand , 2010, The American journal of tropical medicine and hygiene.

[15]  P. Butraporn,et al.  Adherence to Antimalarial Drug Therapy among Vivax Malaria Patients in Northern Thailand , 2009, Journal of health, population, and nutrition.

[16]  G. Brittenham,et al.  High-dose primaquine regimens against relapse of Plasmodium vivax malaria. , 2008, The American journal of tropical medicine and hygiene.

[17]  R. Price,et al.  Clinical and Pharmacological Determinants of the Therapeutic Response to Dihydroartemisinin-Piperaquine for Drug-Resistant Malaria , 2007, Antimicrobial Agents and Chemotherapy.

[18]  S. Pocock,et al.  Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. , 2006, JAMA.

[19]  N. White,et al.  Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. , 2004, Acta tropica.

[20]  N. Gogtay,et al.  Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections. , 1999, Annals of tropical medicine and parasitology.

[21]  N. White,et al.  Treatment of vivax malaria on the western border of Thailand. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[22]  N. Gogtay,et al.  A 5 days primaquine regimen as anti-relapse therapy for Plasmodium vivax. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[23]  J. Baird,et al.  In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia. , 1997, The American journal of tropical medicine and hygiene.

[24]  S. Pukrittayakamee,et al.  Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. , 1994, The Journal of infectious diseases.

[25]  N. Sitaraman,et al.  Efficacy of 5-day radical treatment of P. vivax infection in Tamil Nadu. , 1977, The Indian journal of medical research.

[26]  D. Clyde,et al.  Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. , 1977, The American journal of tropical medicine and hygiene.

[27]  W. Collins,et al.  Five day primaquine therapy--an evaluation of radical curative activity against vivax malaria infection. , 1973, The American journal of tropical medicine and hygiene.

[28]  Margaret Mitchell,et al.  Brief Report: Special Modifications of the Fluorescent Screening Method for Glucose-6-Phosphate Dehydrogenase Deficiency , 1968 .

[29]  Douglas G. Altman,et al.  Reporting of Noninferiority and Equivalence Randomized Trials , 2013 .

[30]  P. Gething,et al.  The global public health significance of Plasmodium vivax. , 2012, Advances in parasitology.

[31]  S. Krudsood,et al.  Directly observed therapy with primaquine to reduce the recurrence rate of plasmodium vivax infection along the Thai-Myanmar border. , 2011, The Southeast Asian journal of tropical medicine and public health.

[32]  Douglas G Altman,et al.  Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. , 2006, JAMA.